Sources

14 Total Sources

Capricor Plunges 55% After FDA Panel Rejects Duchenne Therapy Efficacy

Left20%

Center60%

Right20%

moomoo.com6d ago

Capricor Therapeutics Stock Plunges 55% After FDA Vote Against Duchenne Therapy

FDA panel votes against Capricor's Duchenne heart disease therapy | Reuters

Medpage Today7d ago

FDA Committee Votes Down Duchenne Drug | MedPage Today

FDA Panel Recommends Against Approval of Capricor's Duchenne Drug Deramiocel

Medical Daily7d ago

FDA Advisers Meet Today on a Cell Therapy for the Heart Disease That Now Kills Most Duchenne Patients

Neurology Live7d ago

FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA panel votes against Capricor's Duchenne heart disease therapy | WTVB | 1590 AM · 95.5 FM | The Voice of Branch County

The Wall Street Journal7d ago

FDA Advisory Panel Votes Against Capricor Therapy

FDA reviewers vote against approval of Capricor's DMD therapy in chaotic adcomm meeting - BioSpace

Yahoo! Voices6d ago

FDA panel votes against Capricor's Duchenne heart disease therapy

Stocktwits7d ago

Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In

GuruFocus.com7d ago

FDA Advisory Panel Skeptical on CAPR's Duchenne Cardiomyopathy T

Fierce Biotech7d ago

FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute | Fierce Biotech

intellectia.ai7d ago

Capricor Faces Pivotal FDA Meeting on Deramiocel | Intellectia.AI